This site complies with the HONcode standard for trustworthy health information:
verify here.

Rewarding for
you and us
Defeat Diabetes Foundation

Defeat Diabetes
Foundation
150 153rd Ave,
Suite 300
Madeira Beach, FL 33708

Drugs » Actos

Search our News Articles Archives for diabetes and health news. Search by word or phrase. The latest article will appear first.

More Evidence of Increased Fractures With Thiazolidinediones

Posted: Wednesday, June 25, 2008

Further evidence that long-term use of the thiazolidinediones rosiglitazone and pioglitazone may increase risk of fractures (particularly of the hip and wrist) has come from a new case-control study.

Diabetes Prevention Hopes Revived for Thiazolidinedione

Posted: Friday, June 20, 2008

Pioglitazone (Actos) may prevent or delay progression to diabetes for patients with pre-diabetes by 81%, researchers found.

Glitazones No Better than Older Drugs for Type 2 Diabetes

Posted: Friday, April 18, 2008

The class of glitazone diabetes drugs offer no benefits as monotherapy compared with older, less expensive drugs, according to the authors of an analysis of data from recent clinical trials.

Pioglitazone Lowers Cardiovascular Risk in Diabetic Patients with Kidney Disease

Posted: Thursday, December 27, 2007

A new study confirms that chronic kidney disease (CKD) increases the already-high risk of serious cardiovascular events in diabetic patients with damage to the large blood vessels and suggests that treatment with the anti-diabetic drug pioglitazone may help to lower this risk.

Increased Serious Heart Failure Incidence With Pioglitazone

Posted: Thursday, December 06, 2007

According to a new report in Diabetes Care, pioglitazone use is associated with an increased incidence of serious heart failure, but still provides clinical benefits, with no evidence that it increases subsequent mortality and morbidity

Actos Showed Improvement in Diabetes and Macrovascular Disease

Posted: Thursday, October 11, 2007

Long-term therapy with pioglitazone in patients with cardiovascular disease and type 2 diabetes not only reduces risk of death, myocardial infarction, or stroke, but it also has favourable effects on lipid markers in patients on statin therapy.